Device Versacross Access Solution_icg

Versacross Access Solution

Payments companies reported to CMS as associated with Versacross Access Solution. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.4Massociated payments (2023-2025)
1,162clinicians with associated payments
1company reporting

By year

2023 $465K
2024 $525K
2025 $420K

Payments reported as associated with Versacross Access Solution, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $465K
Interventional Cardiology $432K
Clinical Cardiac Electrophysiology $364K
Internal Medicine $39K
Hospitalist $7,821
Nurse Anesthetist, Certified Registered $7,117

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Versacross Access Solution

These are the largest totals companies reported as associated with Versacross Access Solution. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Augustin Delago Albany, NY Cardiovascular Disease $227,568.98
David Callans Philadelphia, PA Clinical Cardiac Electrophysiology $42,516.99
Matthew Hyman Philadelphia, PA Clinical Cardiac Electrophysiology $37,231.39
Gagan Singh Sacramento, CA Cardiovascular Disease $31,874.02
Saurabh Sanon Largo, FL Interventional Cardiology $29,112.20
Jason Chinitz Bay Shore, NY $27,568.67
Paul Mahoney Greenville, NC Interventional Cardiology $26,835.44
Douglas Ebersole Lakeland, FL Interventional Cardiology $25,138.04
Bibhu Mohanty Tampa, FL Interventional Cardiology $19,124.16
Christopher Ellis Nashville, TN Cardiovascular Disease $18,904.12

Prescribed Versacross Access Solution?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.